Objective: To detect the relationship between CTGF in the bone marrow of MM patients and osteolytic lesion of myeloma, moreover, to investigate the clinical significance of CTGF in MM.
Methods: Fifity-four MM patients treated in our hospital from March 2019 to April 2020 were enrolled, and 28 healthy volunteers were selected as the control group. The plasma in bone marrow of the patients was collected, and the ELISA was used to detect the level of CTGF in bone marrow plasma and the relationship between its and clinical characteristics were statistically analyzed.
Results: The CTGF level of MM patients was significantly higher than those in the healthy control group (P<0.001); the CTGF level in male patients was higher than that in female patients (P=0.007); the CTGF level in MM patients with osteolytic lesions was significantly higher than patients without osteolytic lesions and controls (P=0.007, P=0.001). The CTGF level in MM patients was positively correlated with the number of bone lesions (P<0.001, r=0.52). CTGF levels in patients with ≥3 bone lesions were significantly higher than those with <3 bone lesions and without bone lesions (P=0.014, P=0.002). ROC curve result showed that CTGF expression level shows a significant diagnostic value for MM bone disease (P<0.001).
Conclusion: The abnormally high expression of CTGF level in MM patients is related to the degree of myelomas osteolytic lesions and can reflect the progress of MM.
题目: CTGF在多发性骨髓瘤患者中的表达及临床意义.
目的: 研究多发性骨髓瘤（MM）患者骨髓中结缔组织生长因子（CTGF）水平及其与骨髓瘤溶骨性病变的关系，探讨CTGF在多发性骨髓瘤骨病中的临床意义.
方法: 选取2019年3月-2020年4月在本院接受治疗的MM患者54例，同时选取28例健康志愿者作为对照组，收集受试者骨髓后分离骨髓上清，采用双抗体夹心酶标免疫分析法（ELISA）检测骨髓上清液中CTGF蛋白表达水平，分析其与临床相关指标之间的关系.
结果: MM患者的CTGF水平显著高于健康对照组 （P<0.001）；男性患者CTGF水平明显高于女性患者（P=0.007）；有骨病组的MM患者CTGF水平明显高于无骨病组的患者和对照组（P=0.007，P=0.001）。 MM患者的CTGF水平与骨损害的病灶数呈正相关（r=0.52），≥3处骨损害患者骨髓CTGF水平显著高于<3处骨损害患者和无骨损害患者 （P=0.014，P=0.002）。ROC曲线结果表明，CTGF表达水平对于MM骨病的诊断有显著的价值（P<0.001）.
结论: MM患者CTGF水平异常高表达与骨髓瘤溶骨性病变的程度相关，能反映MM疾病的进展.